A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
Completed · Phase 1 · NCT06824051
Conditions: Obesity, Overweight
At a glance
- Research payments reported, 2025
- $3.6M
- U.S. investigators named
- 4
- Sites paid
- 5
- Planned or actual enrollment
- 120
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Orforglipron (drug), Placebo (drug)
- Dates
- Started 2025-02-17; completion 2026-01-26
- Results posted
- Not yet
The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.
From ClinicalTrials.gov, last updated 2026-02-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $3.6M in research payments for this study in 2025 (12 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alexander N. Prezioso, M.D. Specialist · Lake Hopatcong, NJ
- Richard Sanders Psychiatry · Dayton, OH
- John G. Mickelson, DO Family Medicine · Lincoln City, OR
- Nitendra P. Agarwal, M.D., M.P.H. Hospitalist · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Erg Holding Co LLC DBA St Louis Clinical Trials LLC $2.5M
- Axis Clinicals LLC $944,308
- Axis Clinical Trials $28,576
- Clinical Pharmacology of Miami Inc $23,156
- Endeavor Clinical Trials PA $21,288
- $9,155
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.